Inventor · disambiguated record
Bernhard Fasching
Also filed as: FASCHING BERNHARD
6 granted patents·16 pending applications·4 citations·filing 2018–2025
71Inventor score
Top patents by PatentIndex Score
22 records- 0188US11912682B2Isoindolinone compoundsMONTE ROSA THERAPEUTICS INC·Filed 2023·Granted Feb 27, 2024·2 cites·7 claims
- 0273US10807973B2Compounds for use as therapeutically active substances in the treatment of retinal diseasesENDOGENA THERAPEUTICS INC·Filed 2018·Granted Oct 20, 2020·1 cites·40 claims
- 0371US12391663B2Isoindolinone compoundsMONTE ROSA THERAPEUTICS AG·Filed 2023·Granted Aug 19, 2025·0 cites·20 claims
- 0471US10752593B2Compounds for use as therapeutically active substances in the treatment of retinal diseasesENDOGENA THERAPEUTICS INC·Filed 2018·Granted Aug 25, 2020·1 cites·38 claims
- 0568US12459920B2Targeted protein degradationMONTE ROSA THERAPEUTICS AG·Filed 2025·Granted Nov 4, 2025·0 cites·5 claims
- 0668US2025340528A1Targeted protein degradationMONTE ROSA THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0762US12195452B2N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2025·0 cites·19 claims
- 0860US2025115582A1Molecular glue degraders and methods of using the sameMONTE ROSA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0960US2025171420A1Molecular glue degraders and methods of using the sameMONTE ROSA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1060US2025115581A1Substituted piperidines as ck1a degradersMONTE ROSA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1160US2024299559A1Compounds that mediate protein degradation and methods of use thereofMONTE ROSA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1259US2024051936A1Isoindolinone compoundsMONTE ROSA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1359US2024051937A1Isoindolinone amide compounds useful to treat diseases associated with gspt1MONTE ROSA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1457US2024308976A1Compounds that mediate protein degradation and uses thereofMONTE ROSA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1557US2024294495A1Compounds that mediate protein degradation and methods of use thereofMONTE ROSA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1656US2024317706A1Compounds that mediate protein degradation and methods of use thereofMONTE ROSA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1756US2024216355A1Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codonsMONTE ROSA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1853US2022242846A1Isoindolinone compoundsMONTE ROSA THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1952US2025205219A1Targeted degradation of vav1MONTE ROSA THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 2051US2025263395A1Compounds that mediate protein degradation and methods of use thereofMONTE ROSA THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 2143US2022089547A1Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2236US2025257048A1Methods of preparing an isoindolinone derivative and crystal forms thereofMONTE ROSA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bernhard Fasching files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →